Emerging therapies: controlling glucose homeostasis, immunotherapy, islet transplantation, gene therapy, and islet cell neogenesis and regeneration.
Ruggles
James A
JA
Amylin Pharmaceuticals, 9373 Towne Centre Drive, San Diego, CA 92121, USA.
Kelemen
Donald
D
Baron
Alain
A
D001786:Blood Glucose / Q000378:metabolism*; D002454:Cell Differentiation; D002455:Cell Division; D003922:Diabetes Mellitus, Type 1 / Q000628:therapy*; D000077270:Exenatide; D015316:Genetic Therapy; D005934:Glucagon / Q000627:therapeutic use; D052216:Glucagon-Like Peptide 1; D006706:Homeostasis; D006801:Humans; D007167:Immunotherapy; D007515:Islets of Langerhans / Q000166:cytology*; D016381:Islets of Langerhans Transplantation; D010446:Peptide Fragments / Q000627:therapeutic use; D010455:Peptides / Q000627:therapeutic use; D011498:Protein Precursors / Q000627:therapeutic use; D013234:Stem Cells / Q000166:cytology; D014688:Venoms / Q000627:therapeutic use
D001786:Blood Glucose; D010446:Peptide Fragments; D010455:Peptides; D011498:Protein Precursors; D014688:Venoms; D052216:Glucagon-Like Peptide 1; D005934:Glucagon; D000077270:Exenatide